Ras isoform abundance and signalling in human cancer cell lines.

Area of Science:

• Molecular Biology
• Cell Signaling
• Oncology

Background:

• The Ras signaling pathway is crucial for cell growth and differentiation.
• H-, K-, and N-Ras are major isoforms with distinct biological roles.
• Understanding isoform-specific activation and downstream effects is key in cancer research.

Purpose of the Study:

• To compare the activation efficiencies of different Ras isoforms by growth factors.
• To investigate the role of specific Ras isoforms in downstream pathway activation.
• To analyze Ras isoform contribution in cancer cell lines and the impact of oncogenic mutations.

Main Methods:

• Stimulation of Ras isoforms with epidermal or hepatocyte growth factor.
• Inhibition of receptor endocytosis to study Ras activation dynamics.
• Small interfering RNA (siRNA) mediated acute knockdown of individual Ras isoforms.
• Quantitative profiling of Ras isoform contribution to the total Ras pool in cancer cell lines.

Main Results:

• Ras isoform activation efficiencies are conserved across different stimuli.
• Receptor endocytosis inhibition selectively reduced N- and H-Ras activation, sparing K-Ras.
• Cancer cell lines exhibit diverse Ras isoform abundance, typically K>=N>>H.
• Oncogenic Ras mutations in cancer cells correlated with attenuated canonical effector pathway activation.
• Endogenous Ras isoforms demonstrated no specific coupling to Raf or PtdIns-3-kinase pathways.

Conclusions:

• Ras isoform activation is influenced by receptor endocytosis.
• Isoform-specific contributions to the Ras pool vary significantly in cancer.
• Oncogenic Ras mutations may alter downstream signaling outcomes differently than previously thought.
• Ras isoforms do not show preferential coupling to major downstream effectors like Raf and PtdIns-3-kinase.